EP Patent

EP4041226A1 — Combinations of gaba-a receptor positive allosteric modulators and nmda antagonists, nmda negative allosteric modulators or nmda partial agonists

Assigned to Praxis Precision Medicines Inc · Expires 2022-08-17 · 4y expired

What this patent protects

The invention relates to combinations of GABA-A Receptor positive allosteric modulators and NMDA antagonists, NMDA Negative Allosteric Modulators or NMDA partial agonists and methods using such combinations to treat mood disorders, such as depression and anxiety.

USPTO Abstract

The invention relates to combinations of GABA-A Receptor positive allosteric modulators and NMDA antagonists, NMDA Negative Allosteric Modulators or NMDA partial agonists and methods using such combinations to treat mood disorders, such as depression and anxiety.

Drugs covered by this patent

Patent Metadata

Patent number
EP4041226A1
Jurisdiction
EP
Classification
Expires
2022-08-17
Drug substance claim
No
Drug product claim
No
Assignee
Praxis Precision Medicines Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.